← back to search

Uwe Haberkorn

Heidelberg University · DE
Area of research
Radiology, Nuclear Medicine and Imaging · Pulmonary and Respiratory Medicine
Research interest
Research interests include Radiopharmaceutical Chemistry and Applications, Prostate Cancer Treatment and Research, Medical Imaging Techniques and Applications, and Peptidase Inhibition and Analysis.
h-index
108
citations
46,683
works
763
NIH funding
primary concept
Medicine
email

Recent publications

Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial
Journal for ImmunoTherapy of Cancer 2025cited by 3position: middledoi
68Gallium-labelled fibroblast activation protein inhibitor uptake in joints: a single-center cohort analysis of 268 patients
European Journal of Nuclear Medicine and Molecular Imaging 2025cited by 1position: middledoi
Immunohistochemical FAP Expression Reflects<sup>68</sup>Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Ductal Adenocarcinoma
Journal of Nuclear Medicine 2024cited by 36position: middledoi
Deescalated<sup>225</sup>Ac-PSMA-617 Versus<sup>177</sup>Lu/<sup>225</sup>Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients
Journal of Nuclear Medicine 2024cited by 28position: middledoi
Fibroblast activation protein inhibitor-positron emission tomography in aortitis: fibroblast pathology in active inflammation and remission
Lara D. Veeken 2024cited by 22position: middledoi
1,090 Publications and 5 Years Later: Is FAP-Targeted Theranostics Really Happening?
Journal of Nuclear Medicine 2024cited by 9position: firstdoi
Conjugation of Polycationic Peptides Extends the Efficacy Spectrum of β‐Lactam Antibiotics
Advanced Science 2024cited by 5position: middledoi
Enhancing the diagnostic capacity of [18F]PSMA-1007 PET/MRI in primary prostate cancer staging with artificial intelligence and semi-quantitative DCE: an exploratory study
EJNMMI Reports 2024cited by 3position: middledoi
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
European Journal of Nuclear Medicine and Molecular Imaging 2023cited by 346position: middledoi
FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease
Radiology 2023cited by 319position: lastdoi
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
European Journal of Nuclear Medicine and Molecular Imaging 2023cited by 243position: middledoi
FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease.
2023cited by 241position: contributordoi
Radiotheranostics in oncology: Making precision medicine possible
CA A Cancer Journal for Clinicians 2023cited by 114position: lastdoi
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
Nature Communications 2023cited by 35position: middledoi
Impact of<sup>68</sup>Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers
Journal of Nuclear Medicine 2023cited by 33position: middledoi
PSMA-GCK01: A Generator-Based<sup>99m</sup>Tc/<sup>188</sup>Re Theranostic Ligand for the Prostate-Specific Membrane Antigen
Journal of Nuclear Medicine 2023cited by 24position: middledoi
Molecular Imaging of Myocardial Fibroblast Activation in Patients with Advanced Aortic Stenosis Before Transcatheter Aortic Valve Replacement: A Pilot Study
Journal of Nuclear Medicine 2023cited by 24position: middledoi
Comparison of early and late 68Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas
Scientific Reports 2023cited by 19position: middledoi
Repetitive Early<sup>68</sup>Ga-FAPI PET Acquisition Comparing<sup>68</sup>Ga-FAPI-02,<sup>68</sup>Ga-FAPI-46, and<sup>68</sup>Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions
Journal of Nuclear Medicine 2022cited by 58position: middledoi
[68 Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease
European Journal of Nuclear Medicine and Molecular Imaging 2022cited by 54position: middledoi
Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74
Cancers 2022cited by 23position: middledoi
Effects of Different Basal Cell Culture Media upon the Osteogenic Response of hMSCs Evaluated by 99mTc-HDP Labeling
International Journal of Molecular Sciences 2022cited by 18position: middledoi
Advancement and Future Perspective of FAPI PET/CT In Gynecological Malignancies
Seminars in Nuclear Medicine 2022cited by 17position: middledoi
Impact of Linker Modification and PEGylation of Vancomycin Conjugates on Structure-Activity Relationships and Pharmacokinetics
Pharmaceuticals 2022cited by 9position: middledoi
A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer
Pharmaceuticals 2022cited by 8position: middledoi
The impact of tumor metabolic activity assessed by 18F-FET amino acid PET imaging in particle radiotherapy of high-grade glioma patients
Frontiers in Oncology 2022cited by 8position: middledoi
Dual-Layer Spectral Detector CT in Comparison with FDG-PET/CT for the Assessment of Lymphoma Activity
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 2022cited by 5position: middledoi
Detecting and Locating the Site of Local Relapse Using 18F-PSMA-1007 Imaging After Primary Treatment of 135 Prostate Cancer Patients—Potential Impact on PSMA-Guided Radiation Therapy
Molecular Imaging and Biology 2022cited by 5position: middledoi
Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617
Frontiers in Chemistry 2022cited by 4position: middledoi
FAP-Specific Signalling Is an Independent Diagnostic Approach in ACC and Not a Surrogate Marker of MRI Sequences
Cancers 2022cited by 4position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Frederik L. Giesel · Düsseldorf University Hospital114 papers (2012–2024)Clemens Kratochwil · German Center for Lung Research112 papers (2012–2024)Klaus Kopka · Helmholtz-Zentrum Dresden-Rossendorf77 papers (2014–2022)Walter Mier · Heidelberg University65 papers (2012–2024)Jürgen Debus · NYU Langone Health56 papers (2012–2023)Ali Afshar‐Oromieh · University Hospital of Bern48 papers (2012–2021)Matthias Eder · German Cancer Research Center44 papers (2012–2022)Hendrik Rathke · Kantonsspital Graubünden32 papers (2017–2024)Antonia Dimitrakopoulou‐Strauss · German Cancer Research Center32 papers (2012–2024)Tim Holland-Letz · Heidelberg University31 papers (2012–2021)Paul Flechsig · University Hospital Heidelberg29 papers (2015–2020)Christos Sachpekidis · German Cancer Research Center29 papers (2014–2024)Boris Hadaschik · Deutsche Gesellschaft für Urologie27 papers (2012–2021)Manuel Röhrich · University of Applied Sciences Mainz26 papers (2018–2025)Annette Altmann · German Cancer Research Center25 papers (2012–2024)Martin Schäfer · German Cancer Research Center24 papers (2012–2022)Hans‐Ulrich Kauczor · German Cancer Research Center22 papers (2015–2025)Thomas Lindner · University of Regensburg22 papers (2018–2021)Stefan A. Koerber · Krankenhaus Barmherzige Brüder20 papers (2017–2023)Ulrike Bauder‐Wüst · German Cancer Research Center18 papers (2012–2022)